Posted on: 03/10/2007

Neurology. 2007 Feb 27;68(9):688-90. Related Articles, Links

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J, Jauch T, Koch H, Bogdahn U.

Department of Neurology, District Medical Center, University of Regensburg, Regensburg, Germany.

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

PMID: 17325277 [PubMed - in process]


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!